India Glycols Limited (NSE:INDIAGLYCO)
India · Delayed Price · Currency is INR | Market Cap | 20.70B -66.6% |
| Revenue (ttm) | 43.01B +12.0% |
| Net Income | 3.16B +29.8% |
| EPS | 48.68 +23.6% |
| Shares Out | n/a |
| PE Ratio | 6.34 |
| Forward PE | n/a |
| Dividend | 12.50 (4.05%) |
| Ex-Dividend Date | Mar 23, 2026 |
| Volume | 306,855 |
| Open | 311.85 |
| Previous Close | 308.35 |
| Day's Range | 308.40 - 317.75 |
| 52-Week Range | 217.00 - 1,222.00 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About India Glycols
India Glycols Limited manufactures and sells bio-based specialities and performance chemicals in India and internationally. It operates through Bio-based Specialities and Performance Chemicals, Potable Spirits, Ennature Biopharma, and Bio-Fuel segments. The company offers bio mono ethylene, di ethylene, and tri ethylene glycols; ethylene and diethylene glycol monoethyl ethers, ethylene and diethylene glycol monoethyl ether acetates, and brake fluids; biopolymers from agricultural guar gum, tamarind gum, and cassia gum; biofuels, which include e... [Read more]
Financial Performance
In fiscal year 2026, India Glycols's revenue was 42.11 billion, an increase of 11.76% compared to the previous year's 37.68 billion. Earnings were 2.93 billion, an increase of 26.78%.
Financial StatementsNews
India Glycols Transcript: Q1 26/27
Q1 FY27 delivered 9% consolidated net revenue growth, 13% EBITDA growth and a 15% EBITDA margin. Spirits, chemicals and biopharma advanced, while restructuring progressed; input and freight volatility remained key headwinds.
India Glycols Slides: Q1 2027
India Glycols has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 14, 2026.
India Glycols Quarterly report: Q1 2027
India Glycols has published its Q1 2027 quarterly earnings report on August 14, 2026.
India Glycols Transcript: Q4 25/26
FY26 revenue and EBITDA grew, with biofuels and potable spirits leading; debt reduction and margin gains strengthened results. Management sees growth opportunities in premium spirits and performance chemicals, while geopolitical and input-cost risks persist.
India Glycols Slides: Q4 2026
India Glycols has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 18, 2026.
India Glycols Quarterly report: Q4 2026
India Glycols has published its Q4 2026 quarterly earnings report on May 18, 2026.
India Glycols Annual report: Q4 2026
India Glycols has published its Q4 2026 annual report on May 18, 2026.
India Glycols Q4 results: Net profit rises 27% YoY as margins improve on strong operational performance
India Glycols reported a strong operational performance for Q4 FY26, with growth in revenue, EBITDA and profitability supported by margin expansion and improved business mix. The company reported cons...
India Glycols secures 100% approval for scheme of arrangement at creditors meeting
India Glycols Limited announced that the scheme of arrangement involving Ennature Bio Pharma Limited and IGL Spirits Limited has been approved with a 100% vote in favour by its unsecured…
India Glycols board declares Rs 7.5 interim dividend for FY26
India Glycols Limited has announced an interim dividend of ₹7.5 per equity share for the financial year 2025–26, offering a strong reward to shareholders. The decision was approved by the…
India Glycols Transcript: Q3 25/26
Record 9M revenue and EBITDA growth was led by spirits, biofuels, and improving chemical margins. Debt reduction and premium product launches support the outlook, while global volatility and feedstock costs remain risks.
India Glycols Slides: Q3 2026
India Glycols has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
India Glycols Quarterly report: Q3 2026
India Glycols has published its Q3 2026 quarterly earnings report on February 12, 2026.
India Glycols Transcript: Q2 25/26
Q2 and H1 growth was led by biofuels and potable spirits, lifting EBITDA margins. Chemicals and Ennature faced market and supply pressures; a ₹467 crore preferential issue is intended to reduce debt.
India Glycols Slides: Q2 2026
India Glycols has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 18, 2025.
India Glycols Quarterly report: Q2 2026
India Glycols has published its Q2 2026 quarterly earnings report on November 18, 2025.
India Glycols shares rally over 5% after strong Q2 results; Net profit jumps 30.9% YoY to Rs 65.1 crore, revenue up 13.6%
India Glycols saw its stock jump more than 5% in Monday’s trade after the company posted a solid set of...
India Glycols Transcript: Q1 25/26
Net revenue rose 7% YoY, EBITDA 18% and PAT 21%, led by biofuels, potable spirits and stronger JV earnings. Chemicals and biopharma remained under pressure; FY26 CapEx is expected to be limited.
India Glycols Slides: Q1 2026
India Glycols has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 11, 2025.
India Glycols Quarterly report: Q1 2026
India Glycols has published its Q1 2026 quarterly earnings report on August 11, 2025.
India Glycols Transcript: Q4 24/25
FY25 growth was led by biofuels and potable spirits, lifting earnings and margins despite softer quarterly net revenue. Management expects continued spirits and ethanol growth, with limited major CapEx and scheduled debt repayment supported by cash profit.
India Glycols Slides: Q4 2025
India Glycols has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on May 21, 2025.
India Glycols Quarterly report: Q4 2025
India Glycols has published its Q4 2025 quarterly earnings report on May 21, 2025.
India Glycols Annual report: Q4 2025
India Glycols has published its Q4 2025 annual report on May 21, 2025.
India Glycols receives EIR from USFDA for nutraceuticals products and dietary supplements ingredients at Dehradun plant
India Glycols Limited (IGL) has achieved a significant milestone by receiving the Establishment Inspection Report (EIR) with no observations from the U.S. Food and Drug Administration (USFDA) on April...